Biosciences' lead drug candidate, VE303, has been reported to demonstrate efficacy in preventing recurrent Clostridioides ...
Vedanta Biosciences has published additional results from its Phase 2 CONSORTIUM study for VE303, a potential first-in-class ...
Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases, today announced the publication of additional results ...
PureTech Health (PRTC) noted that its founded entity, Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia ...
Vedanta Biosciences is a clinical-stage biopharmaceutical company developing medicines for the treatment of gastrointestinal diseases. The company's lead assets are potential first-in-class oral ...
Trends such as bacteriophages and medicinal drugs derived from them are gaining popularity. Companies like Vedanta Biosciences and Finch Therapeutics are leading the way with novel drugs like CP101 ...
Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases, today announced the publication of additional results from ...
Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases, today announced the publication of additional results ...
CAMBRIDGE, Mass., January 23, 2025--(BUSINESS WIRE)--Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases ...
11d
Topline data for the ongoing Phase 3 pivotal RESTORATiVE303 study are expected in 2026 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback